Executive Order 13944 signed by President Trump on August 6, 2020 aims to:

• A. Expanding international manufacturing
• B. Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs Are Made in the United States
• C. Reduce FDA oversight
• D. Promote foreign sourcing of critical inputs

Answer: (B)

Understanding how policy actions shape the pharmaceutical supply chain, particularly in securing domestic production for essential medicines and medical countermeasures. Executive Order 13944 is aimed at strengthening U.S. manufacturing for essential medicines, medical countermeasures, and other critical inputs, to reduce reliance on foreign sources and improve readiness in health emergencies. That focus on bringing production home is why the best choice is that it seeks to ensure these items are Made in the United States.

The other options describe directions that run counter to this aim. Expanding international manufacturing or promoting foreign sourcing would increase dependence on outside the U.S., not reduce it. Reducing FDA oversight would undermine safety and regulatory controls, which is not the intent of the order.